1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

ESMO 24: Nuvation One Step Ahead In Race For ROS1 Lung Cancer Niche

 
• By Andrew McConaghie

Two similarly named companies, Nuvation and Nuvalent, are racing to see who can claim best-in-class status in next-generation lung cancer therapies.

ESMO
• Source: ESMO

Nuvation Bio has presented new pivotal trial data which could give its next-generation ROS1 inhibitor taletrectinib best-in-class status.

But its rival and near-namesake Nuvalent is hot on its heels with a candidate from the same class, zidesamtinib....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

AstraZeneca Launches At-Home Flu Vaccine Amid Industry DTC Push

 
• By Alaric DeArment

The drugmaker announced the launch of an at-home version of its nasal FluMist vaccine, as more companies are looking into direct-to-patient drug sales in response to Trump’s most favored nation pricing proposals.

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By Vibha Ravi

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 
• By Alaric DeArment

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.